Update: Halaven (eribulin mesylate) Now FDA Approved - November 15, 2010
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
TOKYO and WOODCLIFF LAKE, N.J., February 01, 2008 /PRNewswire/ -- Eisai Co., Ltd. and Eisai's U.S. subsidiary, Eisai Corporation of North America (Headquarters: New Jersey, the United States, Chairman & CEO: Hajime Shimizu), today announced a change in the schedule for submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for E7389 (generic name: eribulin mesylate) for third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine.
Eisai is committed to developing E7389 as a potential treatment for patients with advanced breast cancer. In a Phase II study of 299 patients with advanced breast cancer who had been heavily pretreated, the compound has shown promising anti-tumor activity, with a response rate of 14.1% by investigator evaluation and 9.3% by independent radiologist evaluation. It has also been shown in the Phase II study to be generally well-tolerated, with the most common Grades 3 and 4 drug-related adverse events being 54% in neutropenia and 14% in leucopenia. Grade 3 peripheral neuropathy occurred in 6% of study participants, and there were no Grade 4 events.
Eisai had planned to submit an NDA under Subpart H*, based on Phase II clinical trial data, to seek accelerated approval for E7389 as a third-line breast cancer treatment (monotherapy), but is precluded from doing so, because FDA approved another drug for this specific indication last October. Eisai remains committed to advancing two Phase III clinical trials for E7389, which are ongoing in the U.S. and in Europe, Study 301 for second-line and Study 305 for third-line breast cancer treatment. Eisai now plans to submit an NDA to FDA with data from these trials and Phase II clinical trial data in fiscal year 2009-2010. In addition, Eisai continues to evaluate E7389 as a potential treatment for a variety of other solid tumors, including non-small cell lung cancer, prostate cancer and sarcoma.
E7389 is a novel compound developed by Eisai as a new potential anti- cancer agent that suppresses the growth of microtubule which is involved in various cellular processes in the body, such as cell division. E7389 is a synthetic analog of halichondrin B, a naturally-occurring compound which was first isolated from a type of marine sponge in 1992.
Eisai has a strong commitment to the development of new oncology medicines to address the unmet medical needs of patients with cancer. Currently, seven other Eisai oncology compounds are in clinical development, in addition to E7389.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Through a global network of research facilities, manufacturing sites and marketing affiliates, Eisai actively participates in all aspects of the worldwide healthcare system.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
*Accelerated Approval under Subpart H:
One of the programs within the FDA that allows earlier, or accelerated, approval of new drugs for serious or life-threatening illnesses that meet certain criteria designated by the regulatory agency.
CONTACT: Judee Shuler, Eisai Corporation of North America,+1-201-746-2241; Corporate Communications Department, Eisai Co., Ltd.,+81-3-3817-5120
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2008
- FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma - January 28, 2016
- FDA Approves Halaven for Late-Stage Breast Cancer - November 15, 2010
- Eisai Announces Extension of FDA Review of Drug Application for Investigational Agent Eribulin Mesylate - August 30, 2010
- Eisai Submits Simultaneous Regulatory Applications for Approval of Eribulin Mesylate in Japan, U.S. and EU - March 31, 2010